Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States

Abstract Background Immune checkpoint inhibitors targeting the programmed cell death protein‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) axis (collectively referred to as PD[L]1i) have demonstrated clinical benefits in non‐small cell lung cancer (NSCLC) patients. The purpose of this United States...

Full description

Bibliographic Details
Main Authors: Rajwanth Veluswamy, Fred R. Hirsch, Emanuela Taioli, Juan Wisnivesky, Ross Strauss, Douglas Harrough, Boxiong Tang, Gisoo Barnes
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Cancer Medicine
Subjects:
non‐small cell lung cancer (NSCLC)
programmed cell death protein 1 (PD‐1)
programmed death ligand‐1 (PD‐L1)
real‐world evidence
treatment patterns
Online Access:https://doi.org/10.1002/cam4.4785

Similar Items

Similar Items